Skip to main content

Table 1 The correlations among p53 codon 72 variants and various patient characteristics

From: Both p53 codon 72 Arg/Arg and pro/Arg genotypes in glioblastoma multiforme are associated with a better prognosis in bevacizumab treatment

 

Patients (n = 99)

codon 72 (No.4)

p value

CC (n = 28)

GG (n = 38)

CG (n = 33)

 

n

%

n

%

n

%

n

%

Age (n = 99)

        

0.035*

  > 60

58

58.59%

21

75.00%

23

60.53%

14

(42.4%)

 

 ≦60

41

41.41%

7

25.00%

15

39.47%

19

(57.6%)

 

Gender (n = 99)

        

0.819

 Male

43

43.43%

13

46.43%

15

39.47%

15

45.45%

 

 Female

56

56.57%

15

53.57%

23

60.53%

18

54.55%

 

Tumor number (n = 99)

        

0.442

 Solitary

78

78.79%

20

71.43%

30

78.95%

28

84.85%

 

 Multiple

21

21.21%

8

28.57%

8

21.05%

5

15.15%

 

Tumor size (n = 99)

        

0.138

  > 3 cm

12

12.12%

6

21.43%

2

5.26%

4

12.12%

 

 ≦3 cm

87

87.88%

22

78.57%

36

94.74%

29

87.88%

 

Tumor occurrence (n = 99)

        

0.531

 Primary

78

78.79%

20

71.43%

31

81.58%

27

81.82%

 

 Recurrence

21

21.21%

8

28.57%

7

18.42%

6

18.18%

 

Bevacizumab (n = 99)

        

0.179

 No used

45

45.45%

13

46.43%

21

55.26%

11

33.33%

 

 Used

54

54.55%

15

53.57%

17

44.74%

22

66.67%

 

LO-16 nt (n = 76, DNA sequencing)

(No. 2; rs17878362)

        

0.804

 Heterozygote loss

6

(7.9%)

3

(13.6%)

0

(0.0%)

3

(12.5%)

 

 Homozygote loss

70

(92.1%)

19

(86.4%)

30

30(100%)

21

(87.5%)

 

11,299 (No.3) (n = 76, DNA sequencing)

        

0.007**

 CC

65

85.53%

15

68.18%

30

100.00%

20

83.33%

 

 CA

8

10.53%

4

18.18%

0

0.00%

4

16.67%

 

 AA

3

3.95%

3

13.64%

0

0.00%

0

0.00%

 
  1. Chi-squared test. *p < 0.05, **p < 0.001, Statistical significance